Antipsychotic medication for childhood-onset schizophrenia

Cochrane Database of Systematic Reviews

Volumn , Issue 3, 2007, Pages

  Kennedy, Eilis ^a   Kumar, A ^b   Datta, S S ^b  

^a TAVISTOCK CLINIC   (United Kingdom)

^b NONE

Author keywords

Age of onset; Antipsychotic agents *therapeutic use ; Child; Humans; Randomized controlled trials as topic; Schizophrenia *drug therapy

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ANTICHOLINERGIC EFFECT; CLINICAL TRIAL; DROWSINESS; DRUG EFFECT; DRUG WITHDRAWAL; ENURESIS; EXTRAPYRAMIDAL SYMPTOM; HOSPITAL ADMISSION; HUMAN; HYPERSALIVATION; HYPERTENSION; MENTAL CONCENTRATION; META ANALYSIS; MOTOR DYSFUNCTION; NEGATIVE SYNDROME; NEUROLEPTIC MALIGNANT SYNDROME; NEUTROPENIA; ONSET AGE; PATIENT SATISFACTION; POSITIVE SYNDROME; QUALITY OF LIFE; REVIEW; SCHIZOPHRENIA; SEIZURE; SIDE EFFECT; SOMNOLENCE; SUICIDE ATTEMPT; SYSTEMATIC REVIEW; TREATMENT RESPONSE; WEIGHT GAIN;

EID: 39749143011     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD004027.pub2     Document Type: Review

References (90)

1. Engelhardt 1973 {published data only} Engelhardt DM, Polizos P, Waizer J, Hoffman SP. A double blind comparison of fluphenazine and haloperidol in outpatient schizophrenic children. Journal of Autism and Childhood Schizophrenia 1973;3(2):128-37.
2. Faretra 1970 {published data only} Faretra G, Dooher L, Dowling J. Comparison of haloperidol and fluphenazine in disturbed children. American Journal of Psychiatry 1970;126:1670-3. [MEDLINE: 5443653].
3. Kumra 1996 {published data only} Huffman GB. Efficacy of clozapine for schizophrenia in children. American Family Physician 1997;55(4):1356. [MEDLINE: 8936902].
4. Kumra S, Frazier JA, Jacobsen LK, McKenna K, Gordon CT, Lenane MC, Hamburger SD, Smith AK, Albus KE, Alaghband Rad J, Rapoport JL. Childhood-onset schizophrenia. A double-blind clozapine-haloperidol comparison. Archives of General Psychiatry 1996;53(12):1090-7. [MEDLINE: 97115273].
5. Kumra S, Jacobsen LK, Rapoport JL. Childhood-onset schizophrenia - a double-blind clozapine trial. 149th Annual Meeting of the American Psychiatric Association; 1996 Oct 2 - May 9; New York, USA. 1996.
6. Shaw 2006 {published data only} Shaw P, Sporn A, Gogtay N, Overman GP, Greenstein D, Gochman P, Tossell JW, Lenane M, Rapoport JL. Childhood-onset schizophrenia: a double-blind, randomized clozapine-olanzapine comparison. Archives of General Psychiatry 2006;63(7):721-30. [MEDLINE: 16818861].
7. Xiong 2004 {published data only} Xiong Y. Comparison study of childhood schizophrenia treated with risperidone and chlorpromazine. Guizhou Medical Journal 2004;28(8):697-698.
8. Yao 2003 {published data only} YaoH. A study of risperidone in the treatment of child schizophrenia. Journal of Clinical Psychological Medicine 2003;7468(2):801.
9. Claghorn 1972 *Claghorn JL. A double-blind comparison of haloperidol (haldol) and thioridazine (mellaril) in outpatient children. Current Therapeutic Research 1972;14(12):785-9. [MEDLINE: 4629817].
10. Fish 1966 *Fish B, Shapiro T, Campbell M. Long-term prognosis and the response of schizophrenic children to drug therapy: a controlled study of trifluoperazine. American Journal of Psychiatry 1966;123(1):32-9. [MEDLINE: 66135917].
11. Frazier 1994 *Frazier JA, Gordon CT, McKenna K, LenaneMC, Jih D, Rapoport JL. An open trial of clozapine in 11 adolescents with childhood onset schizophrenia. Journal of the American Academy of Child and Adolescent Psychiatry 1994;33(5):658-63. [MEDLINE: 8056728].
12. Gram 1972 *Gram LF, Rafaelsen OJ. Lithium treatment of psychotic children and adolescents. A controlled clinical trial. Acta Psychiatrica Scandinavica 1972;48(3):253-60. [MEDLINE: 4617490].
13. Lewis 1972 *Lewis PJ, James NM. Haloperidol and chlorpromazine - a double-blind cross-over trial and clinical study in children and adolescents. Australian and New Zealand Journal of Psychiatry 1973;7(1):59-65. [MEDLINE: 73233111].
14. Liang 2003 Liang L. A clinical trial of risperidone in treatment of childhood patients with first-episode schizophrenia. Journal of Clinical Psychological Medicine 2003;13(1):20-1.
15. McGlashan 2003 McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, Woods SW, Hawkins KA, Hoffman RE, Preda A, Epstein L, Addington D, Lindborg S, Trzaskoma Q, Tohen M, Breier A. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. American Journal of Psychiatry 2006;163(5):790-9. [MEDLINE: 16648318].
16. McGlashan TH, Zipursky RB, Perkins DO, Addington J, Woods SW, Miller TJ, Lindborg S, Marquez E, Hawkins K, Hoffman RE. Olanzapine versus placebo treatment of the schizophrenia prodrome: One year results. Schizophrenia Research 2003;60:295. [MEDLINE: 16103032].
17. Nagaraja 1977 *Nagaraja J. Clinical use of haloperidol (serenace) in child psychiatry. Child Psychiatry Quarterly 1977;10(4):14-20.
18. Sikich 2004 Sikich L, Hamer RM, Bashford RA, Sheitman BB, Lieberman JA. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Neuropyschopharmacology 2004;29(1):133-45. [MEDLINE: 14583740].
19. Spencer 1996 Spencer EK, Kafantaris V, Padron G, Maria V, Rosenberg CR. Haloperidol in hospitalized schizophrenic children. In: RichardsonMA, HauglandG editor(s). Use of neuroleptics in children. Washington, USA: American Psychiatric Press Inc, 1996:67-83.
20. Spencer EK, Kafantaris V, Padron-Gayol MV, Rosenberg CR, Campbell M. Haloperidol in schizophrenic children: early findings from a study in progress. Psychopharmacology Bulletin 1992;28(2):183-6. [MEDLINE: 1513922].
21. Tandon 2005 Tandon R, Sitholey P, Katiyar M, Kumar A. Short term tolerability of risperidone in children and adolescents with acute and transient psychotic disorders. XIII World Congress of Psychiatry; 2005 10-15th Sept; Cairo, Egypt. 2005.
22. van Nimwegen 2006 van Nimwegen L, de Haan L. Early withdrawal in a double-blind randomized clinical trial with olanzapine and risperidone performed in adolescents with first psychosis. Psychopathology 2006;39(3):158. [MEDLINE: 16531692].
23. Magnuson 2001 Magnuson WG. Childhood onset psychotic disorders: characterization and treatment with atypical neuroleptics / Treatment of childhood onset psychotic disorders with olanzapine or clozapine. National Institutes of Health 2001.
24. AACAP 2001 Mclellan J, Werry J, Bernet W, Arnold V, Beitchman J, Benson R, Buckstein O, Kinlan J, McClellan, Rue D, Shaw J. Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. Journal of the American Academy of Child and Adolescent Psychiatry 2001;40(7 Supplement):4s-23s.
25. Altman 1996 Altman DG, Bland JM. Detecting skewness from summary information. British Medical Journal 1996;313:1200.
26. Alvir 1993 Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA. Clozapine induced agranulocytosis. New England Journal of Medicine 1993;329:162-167.
27. Andreasen 1983 Andreasen NC. The Scale for the Assessment of Negative Symptoms (SANS). Iowa City: The University of Iowa 1983.
28. Andreasen 1984 Andreasen NC. The Scale for the Assessment of Positive Symptoms, (SAPS). Iowa City: The University of Iowa 1984.
29. APA 1980 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders 3rd edition (DSM-III). Washington DC: American Psychiatric Association, 1980.
30. APA 1994 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV). Washington, DC: American Psychiatric Association, 1994.
31. Asarnow 1988 Asarnow JR, Ben-Meir S. Children with schizophrenia spectrum and depressive disorders: a comparative study of premorbid adjustment, onset pattern and severity of impairment. Journal of Child Psychology and Psychiatry 1988;29:477-88.
32. Asarnow 2004 Asarnow Rosenbaum J, Tompson MC, McGrath EP. Annotation: Childhood-onset schizophrenia: clinical and treatment issues. Journal of Child Psychology and Psychiatry 2004;45(2):180-194.
33. Baldessarini 1995 Baldessarini RJ, Teicher M. Dosing of antipsychotic agents in paediatric populations. Journal of Child and Adolescent Psychopharmacology 1995;5(1):1-4.
34. Beitchman 1985 Beitchman JH. Childhood schizophrenia: a review and comparison with adult-onset schizophrenia. Psychiatric Clinics of North America 1985;8:793-814.
35. Bland 1997 Bland JM, Kerry SM. Statistics notes. Trials randomised in clusters. BMJ 1997;315:600.
36. Bleuler 1911 Bleuler E. Dementia praecox oder die gruppe der schizophrenien. Leipzig: Deuticke, 1911.
37. Boissel 1999 Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, Boutitie F, Nony P, Haugh M, Mignot G. The problemof therapeutic efficacy indices. 3. Comparison of the indices and their use. Therapie 1999;54(4):405-11.
38. Bunney 1963 Bunney WEJ, Hamburg DA. Methods for reliable longitudinal observation of behavior. Archives of General Psychiatry 1963;9:280-294.
39. Burd 1987 Burd L, Fischer W, Kerbeshian J. A prevalence study of pervasive developmental disorders in North Dakota. Journal of the American Academy of Child and Adolescent Psychiatry 1987;26(5):700-3.
40. Calderoni 2001 Calderoni D, Wudarsky M, Bhangoo R, Dell ML, Nicolson R, Hamburger S, Gochman P, et al.Differentating childhood-onset schizophrenia from psychotic mood disorders. Journal of the American Academy of Child and Adolescent Psychiatry October 2001;40(10):1191-7.
41. Chalmers 1983 Chalmers TC, Celano P, Sacks HS, Smith H. Bias in treatment assignment in controlled clinical trials. New England Journal of Medicine 1983;309:1358-61.
42. Clark 1988 Clark A F, Lewis S W. Practitioner review: Treatment of schizophrenia in childhood and adolescence. Journal of Child Psychology and Psychiatry 1988;39(8):1071-81.
43. Deeks 2000 Deeks J. Issues in the selection for meta-analyses of binary data: Abstracts of 8th International Cochrane Colloquium. 2000 Oct 25-28th; Cape Town, South Africa.
44. Divine 1992 Divine GW, Brown JT, Frazer LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7:623-9.
45. Donner 2002 Donner A, Klar N. Issues in the meta-analysis of cluster randomized trials. Statistics in Medicine 2002;21:2971-80.
46. Garralda 1984 Garralda M. Hallucinations in children with conduct and emotional disorders; I. The clinical phenomena. Psychological Medicine 1984;14:589-96.
47. Gillberg 1984 Gillberg C. Infantile autism and other childhood psychoses in a sweedish urban region. Epidemiological aspects. Journal of Child Psychology and Psychiatry 1984;25:35-43.
48. Gillberg 1987 Gillberg C, Steffenburg S. Outcome and prognostic factors in infantile autism and similar conditions: a population-based study of 46 cases followed through puberty. Journal of Autism and Developmental Disorders 1987;17:273-87.
49. Gillberg 2001 Gillberg C. Epidemiology of early onset schizophrenia. In: RemschmidtH editor(s). Schizophrenia in children and adolescents. Ist. Cambridge: Cambridge University Press, 2001:43-54.
50. Green 1992 Green W, Padron-Gayol M, Hardesty A, Bassiri M. Schizophrenia with childhood onset: a phenomenological study of 38 cases. Journal of the American Academy of Child and Adolescent Psychiatry 1992;35:968-76.
51. Gulliford 1999 Gulliford MC, Ukoumunne OC, Chinn S. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149:876-83.
52. Guy 1976 Guy U. ECDEU assessment manual for psychopharmacology. Revised. Rockville: National Institute of Mental Health, 1976.
53. Hazell 1995 Hazell Pl, O'Connell D, Heathcote D, Robertson J, Henry D. Efficacy of tricyclic drugs in treating child and adolescent depression. A meta-analysis. British Medical Journal 1995;310:897- 901.
54. Hazell 2001 Hazell P, O'Connell D, Heathcote D, Henry D. Tricyclics in child and adolescent depression. Cochrane Database of Systematic Reviews 2001, Issue 3.
55. Higgins 2003 Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
56. Higgins 2005 Higgins JPT. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. In: HigginsJPT, GreenS editor (s). The Cochrane Library. Chichester, UK: John Wiley & Sons, Ltd, 2005.
57. Hollis 1995 Hollis C. Child and adolescent schizophrenia (juvenile onset) schizophrenia: a case control study of premorbid developmental impairments. British Journal of Psychiatry 1995;166:489-95.
58. Hollis 2000 Hollis C. Adolescent schizophrenia. Advances in Psychiatric Treatment 2000;6:83-92.
59. Hollis 2001 Hollis C. Diagnosis and differential diagnosis. In: RemschmidtH editor(s). Schizophrenia in children and adolescents. 1st Edition. Cambridge: Cambridge University Press, 2001.
60. Jacobsen 1998 Jacobsen LK, Rapoport JL. Research update: Childhood-onset schizophrenia: Implications of clinical and neurobiological research. Journal of Child Psychology and Psychiatry 1998;39(1): 101-13.
61. Jadad 1996 Jadad A, Moore A, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;17:1-12.
62. Kane 1988 Kane J, Honigfield G, Singer J, Meltzer H. Clozapine for treatment-resistant schizophrenia: a double-blind comparison with chlorpromazine. Archives of General Psychiatry 1988;45:789-796.
63. Kanner 1943 Kanner L. Autistic disturbances of affective contact. Nervous child 1943;2:217-50.
64. Kanner 1949 Kanner L. Problems of nosology and psychodynamics of early infantile autism. American Journal of Orthopsychiatry 1949;19:416-26.
65. Kay 1987 Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 1987;13:261-76.
66. Kolvin 1971 Kolvin I. Studies in the childhood psychoses: I. Diagnostic criteria and classification. British Journal of Psychiatry 1971;118:381-84.
67. Kraeplin 1919 Kraeplin E. Dementia praecox and paraphrenia (trans RM Barclay). Edinburgh: Livingstone, 1919.
68. Kumra 1998 Kumra S. Children and adolescents with psychotic disorders. Child Psychopharmacology. Washington DC: American Psychiatric Press, 1998.
69. Marshall 2000 Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176:249-52.
70. McKenna 1994 Mckenna K, Gordon CT, Lenane M, Kaysan D, Fahey K, Rapoport J. Looking for childhood-onset schizophrenia: The first 71 cases screeened. Journal of the American Academy of Child and Adolescent Psychiatry June 1994;33(5):636-44.
71. Moher 2001 Moher D, Schultz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomised trials. Lancet 2001;357:1191-4.
72. Montgomery 1979 Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. British Journal of Psychiatry 1979;134:382-389.
73. Overall 1962 Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychological Reports 1962;10:799-812.
74. Parry-Jones 2001 Parry-Jones WL. Childhood psychosis and schizophrenia: a historical review. In: RemschmidtH editor(s). Schizophrenia in children and adolescents. Ist. Cambridge: Cambridge University Press, 2001:1-23.
75. Remschmidt 1995 Remschmidt H, Schulz E. Psychopharmacology of depressive states in childhood and adolescence. The depressed child and adolescent : Developmental and clinical perspectives. Cambridge: Cambridge University Press, 1995:253-79.
76. Riddle 2001 Riddle MA, Kaselic EA, Frosch E. Paediatric psychopharmocology. Journal of Child Psychology and Psychiatry 2001;42(1):73-90.
77. Russell 1994 Russell AT. The clinical presentation of childhood-onset schizophrenia. Schizophrenia Bulletin 1994;20:631-46.
78. Rutter 1967 Rutter M, Greenfield D, Lockyer L. A five to fifteen year study of infantile psychosis. II. Social behavioural outcome. British Journal of Psychiatry 1967;113:1183-99.
79. Rutter 1972 Rutter M. Childhood schizophrenia reconsidered. Journal of Autism & Childhood Schizophrenia 1972;2:315-37.
80. Schaffer 1983 Schaffer D, Gould MS, Brasic J. A children's global assessment scale (CGAS). Archives of General Psychiatry 1983;40:1228-1231.
81. Schulz 1995 Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-12.
82. Simpson 1970 Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica AActa Psychiatrica Scandinavica 1970;Suppl 212:11-19.
83. Ukoumunne 1999 Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review. Health Technology Assessment 1999;3(5):iii-92.
84. Usiskin 1999 Usiskin SI, Nicolson R, Krasnewich DM, Wenliang Y, Lenane M, Wudarsky M, Hamburger S, Rapoport J. Velocardiofacial syndrome in childhood-onset schizophrenia. Journal of the American Academy of Child and Adolescent Psychiatry 1999;38(12):1536-43.
85. Volkmar 2001 Volkmar FR. Childhood schizophrenia: developmental aspects. In: RemschmidtH editor(s). Schizophrenia in children and adolescents. 1st Edition. Cambridge: Cambridge University Press, 2001.
86. Waraich 2002 Waraich PS, Adams CE, Roque M, Hamill KM, Marti J. Haloperidol dose for the acute phase of schizophrenia. Cochrane Database of Systematic Reviews 2002, Issue 4.Art. No.: CD001951. DOI: 10.1002/14651858.CD001951.
87. Watkins 1988 Watkins JM, Asarnow RF, Tanguay P. Symptom development in childhood onset schizophrenia. Journal of Child Psychiatry and Psychology 1988;29:865-978.
88. Werry 1992 Werry JS. Child and adolescent (early onset) schizophrenia: a review in light of DSM-IIIR. Journal of Autism and Developmental Disorders 1992;22:601-24.
89. WHO 1978 World Health Organisation. International Classification of Diseases (9th Revision) of Mental and Behavioural Disorders. Geneva: WHO, 1978.
90. WHO 1992 World Health Organization. The ICD-10 classification of mental and behavioural disorders. Clinical descriptions and diagnostic guidelines. Geneva: WHO, 1992.